Vall d'Hebron风险评分对缺血性心肌病患者风险分层的价值
本研究纳入673例接受门控SPECT的稳定缺血性心肌病患者,按Vall d'Hebron风险评分(VH-RS)分为4个风险等级,评估其对主要不良心脏事件(MACEs)的分层能力,并探讨血红蛋白(Hb)和估算肾小球滤过率(eGFR)能否提供额外信息。随访(4.8±2.7)年期间379例发生MACEs(0.18/患者/年),VH-RS能有效评估风险,但加入Hb和eGFR变量后整体净重分类改善(NRI)为负值,未改善风险分层性能。
要点
- VH-RS可有效评估稳定缺血性心肌病患者的MACEs风险。
- 加入Hb和eGFR后整体NRI为负值,未改善VH-RS的风险分层。
- 大多数发生MACEs的患者位于极高危(VHRi)等级。
核心结论
- VH-RS能有效评估稳定缺血性心肌病患者的风险。
- 在本研究人群中,加入Hb和eGFR变量未改善VH-RS的性能。
研究设计与样本
- 研究分析了673例连续接受门控SPECT的缺血性心肌病患者。
- 根据VH-RS将患者分为4个风险等级:极低危(VLR)、低危(LR)、中危(MR)和高危(HRi)。
- MACEs定义为非致死性心肌梗死(MI)、心力衰竭住院(HF)、冠状动脉血运重建(CR)和心源性死亡(CD),同时调查了心脏再同步治疗(CRT)和植入式心律转复除颤器(ICD)。
主要发现
- 随访(4.8±2.7)年期间,379例患者发生MACEs(0.18/患者/年)。
- VLR和LR等级无患者,所有患者被重新分类为3个风险等级:MRi=48例、HRi=121例、极高危(VHRi)=504例。
- 大多数发生MACEs的患者位于VHRi等级(趋势检验:无CRT/ICD的MACEs≥1,P<.001;非致死性MI、CD和CR联合,P<.001;有CRT/ICD的MACEs≥1,P<.001)。
- Hb和eGFR值未能适当改善VH-RS获得的风险分层,整体NRI为:无CRT/ICD的MACEs≥1为-10.6%,非致死性MI、CD和CR为-9.08%,有CRT/ICD的MACEs≥1为-8.85%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate the Vall d'Hebron-Risk-Score (VH-RS) to stratify the risk of patients with stable ischemic cardiomyopathy (ICM), and assess whether hemoglobin (Hb) and estimated glomerular filtration rate (eGFR) provide additional information to the VH-RS. METHODS AND RESULTS: We analysed 673 consecutive patients with ICM who underwent gated SPECT. According to VH-RS, we stratified patients into 4-risk-levels: very-low-risk (VLR), low-risk (LR), moderate-risk (MR), and high-risk (HRi). We considered as MACEs: non-fatal myocardial infarction (MI), heart failure hospitalization (HF), coronary revascularization (CR), and cardiac death (CD). Also the cardiac-resynchronization-therapy (CRT), and the implantable-cardioverter-defibrillator (ICD) were investigated. During the follow-up (4.8 ± 2.7 years), 379 patients had MACEs (0.18/patient/year). There were no patients in VLR and LR. All patients were reclassified in 3-risk-levels (MRi = 48; HRi = 121; VHRi[very high risk] = 504). Most patients with MACEs were in VHRi level (test-for-trend: MACEs ≥ 1 without CRT/ICD, P < .001; combined non-fatal MI, CD and CR, P < .001; MACEs ≥ 1 with CRT/ICD, P < .001). The Hb and eGFR values do not properly improve the risk stratification obtained by the VH-RS (global-NRI[net-reclassification-improvement] was: (MACEs ≥ 1 without CRT/ICD: - 10.6%; non-fatal MI, CD and CR: - 9.08%; and MACEs ≥ 1 with CRT/ICD: - 8.85%). CONCLUSION: VH-RS is effective in evaluating risk of patients with stable ICM. In our population, adding Hb and eGFR variables do not improve the performance of the VH-RS.
引用
- Romero-Farina G, Aguadé-Bruix S, Ródenas-Alesina E, et al. Usefulness of the Vall d'Hebron Risk Score to stratify the risk of patients with ischemic cardiomyopathy. J Nucl Cardiol. 2022. PMID: 35941322. doi:10.1007/s12350-022-03074-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。